Spago Nanomedical AB
Research Spago Nanomedical AB (SPAGO) on Bullrun: market cap SEK 91.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPAGO
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 91.81M
- Financial periodQ1 2026
- RevenueSEK 22.00K
- Net income-SEK 6.80M
- Free cash flow-SEK 3.26M
- Gross margin-14981.8%
Valuation Snapshot
latest market cap is SEK 91.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.06 | SEK 29.67M | n/a | SEK 30.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | SEK 91.81M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Spago Nanomedical AB
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Spago Nanomedical AB's market cap?
Spago Nanomedical AB's market capitalization is SEK 91.81M.
What does Spago Nanomedical AB do?
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage.